AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02793947
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Trial: NCT01393522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
Trial: NCT01696656
Drug: Drug prescription pattern
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
Trial: NCT00617747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03937544
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).
Trial: NCT03846544
Drug: Corifollitoropin alfa (CFA)-double pick up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
Trial: NCT02029482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03108066
Drug: MK-3795
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg twice daily (four 200 mg oral tablets twice daily)
Trial: NCT00463008
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06212284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses were gelatine capsules filled with microcrystalline cellulose
Trial: NCT00493311
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo
Trial: NCT00493311
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen solution 1 g / 100 ml
Trial: NCT01869088
Drug: Recombinant Human Adenovirus Type 5 Injection
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
Trial: NCT00860080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Trial: NCT02957617
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
Trial: NCT02775292
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01460602
Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
Trial: NCT03959527
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 1g, oral administration
Trial: NCT00339833
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention was salsalate (3g/day) for 7 days.
Trial: NCT00339833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo for 7 days.
Trial: NCT00700024
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00070564
Drug: AC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00070564
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00070564
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00460239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular; double blind; once per week
Trial: NCT01535443
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Bromfenac Other names: PRO-155
Trial: NCT03131726
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT01407263
Drug: antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vs. three days of antibiotic prophylaxis at catheter removal
Trial: NCT01407263
Drug: Hemostatic Agent
RxNorm normalized name: Hemostatic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
Trial: NCT00533221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Trial: NCT02583022
Drug: Elidel cream 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02654158
Drug: High-dose of Fuganlin Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day
Trial: NCT00650338
Drug: DE-104 ophthalmic solution, low concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application
Trial: NCT00650338
Drug: DE-104 ophthalmic solution, medium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application
Trial: NCT00650338
Drug: DE-104 ophthalmic solution, high concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application
Trial: NCT00650338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02439788
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
Trial: NCT02837302
Drug: Livact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
Trial: NCT01038154
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
Trial: NCT00531947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Trial: NCT02971293
Drug: AZD8871 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive one dose of AZD8871 100 µg single dose DPI.
Trial: NCT02971293
Drug: AZD8871 600 µg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive AZD8871, 600 µg single dose DPI.
Trial: NCT02971293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive Placebo single dose DPI.
Trial: NCT00838383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
Trial: NCT01468571
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
Trial: NCT01468571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks.
Trial: NCT00420628
Drug: loteprednol etabonate/tobramycin opthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Trial: NCT00420628
Drug: vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Trial: NCT00023738
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00048633
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04110886
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, injection, starting dose of 0.2ug escalating up to 20ug
Trial: NCT04110886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, injection matching placebo
Trial: NCT02385110
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
Trial: NCT03142776
Drug: systemic clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00524706
Drug: S-1, oral Leucovorin, Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02136901
Drug: NSAID's and Non-surgical Treatment Options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Trial: NCT02136901
Drug: Intra-Articular Injections with Corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Trial: NCT02714205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Trial: NCT02637310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg/day, Three times a day orally, 2 tablets once, 7 days
Trial: NCT00905567
Drug: Topamax® Tablet 2 x 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02753816
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04346407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
Trial: NCT05076604
Drug: Cardioplegia Solution
RxNorm normalized name: cardioplegia solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.
Trial: NCT02337634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Trial: NCT05076604
Drug: Microplegic Solution No. 1
RxNorm normalized name: microplegic solution no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.
Trial: NCT00184002
Drug: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles.
Trial: NCT00828061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
Trial: NCT02075008
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 120 mg/mL solution for subcutaneous injection
Trial: NCT00408551
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00408551
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04252963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of MUCOLASE tablet
Trial: NCT02465437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
Trial: NCT02465437
Drug: Part B Open-Label Extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JBT-101 20mg bid on Days 1-364
Trial: NCT00540644
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg p.o. BID daily on days 1-21 of each 28 day cycle
Trial: NCT01369745
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 2.7 mg daily
Trial: NCT01067417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Trial: NCT00563914
Drug: ferroquine (SSR97193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: associated with artesunate
Trial: NCT00441870
Drug: EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
Trial: NCT01050322
Drug: Lapatinib Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Trial: NCT00910845
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) injected into the detrusor at Day 1.
Trial: NCT00084227
Drug: Azithromycin/Chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00685360
Drug: Optimized Background Regimen (OBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.
Trial: NCT00685360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching 50-mg tablets of delamanid
Trial: NCT01678664
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
Trial: NCT03171597
Drug: Anti-Platelet Drugs
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including aspirin and clopidogrel, etc.
Trial: NCT03171597
Drug: Lipid Regulating Drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including statins
Trial: NCT03171597
Drug: Coronary Vasodilator
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including nitrates
Trial: NCT03171597
Drug: Xuefu Zhuyu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Trial: NCT03171597
Drug: Gualou Xiebai Banxia Decoction & Danshen Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Trial: NCT03171597
Drug: Shuanghe Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Trial: NCT06361186
Drug: Proximod
RxNorm normalized name: TRACH ADAPT,PROXIMAL FLO SENS R#1050408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple-dose to establish the safety and PK profile
Trial: NCT06361186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo controlled
Trial: NCT02497937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
Trial: NCT02149264
Drug: Testosterone gel (FE 999303)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01610869
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
Trial: NCT00672633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn Oil Pill, 4 pills/day orally for 6 months
Trial: NCT00929344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.